BNXT — BioNxt Solutions Income Statement
0.000.00%
- CA$31.23m
- CA$36.26m
- CA$0.37m
Annual income statement for BioNxt Solutions, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.208 | 0.346 | 0.286 | 0.297 | 0.372 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.199 | 0.196 | 0.372 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.82 | 17.3 | 20.4 | 12.1 | 6.96 |
Operating Profit | -7.61 | -16.9 | -20.1 | -11.8 | -6.58 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.71 | -17.2 | -20.7 | -12.9 | -7.72 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.67 | -16.9 | -20.6 | -12.4 | -7.72 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.67 | -16.9 | -20.6 | -12.4 | -7.72 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.67 | -16.9 | -20.6 | -12.4 | -7.72 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.163 | -0.273 | -0.26 | -0.102 | -0.075 |
Dividends per Share |